Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small cell lung cancer

Medical Oncology

Volumn 23, Issue 3, 2006, Pages 419-422

  Vootukuru, Vidya ^a   Liew, Yin Ping ^b   Nally Jr , Joseph V ^b  

^a ROCHESTER GENERAL HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Acute renal failure; Nephrogenic diabetes insipidus; Pemetrexed; Renal tubular acidosis

Indexed keywords

CYANOCOBALAMIN; GABAPENTIN; INFUSION FLUID; METHYLPHENIDATE; ONDANSETRON; OXYCODONE; PEMETREXED; POTASSIUM; STEROID; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; ADULT; ANAMNESIS; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; HYPOKALEMIA; KIDNEY TUBULE ACIDOSIS; LUNG NON SMALL CELL CANCER; NEPHROGENIC DIABETES INSIPIDUS; NEPHROTOXICITY; POTASSIUM INTAKE; PRIORITY JOURNAL;

ACIDOSIS, RENAL TUBULAR; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DIABETES INSIPIDUS, NEPHROGENIC; FEMALE; GLOMERULAR FILTRATION RATE; GLUTAMATES; GUANINE; HUMANS; KIDNEY FAILURE, ACUTE; KIDNEY TUBULES; LUNG NEOPLASMS; MIDDLE AGED;

EID: 33749379201     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:3:419     Document Type: Article

References (4)

1. Rinaldi DA, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999;44: 372-380.
2. Socinski MA, Stinchcombe TE, Hayes DN. The evolving role of pemetrexed (Alimta) in lung cancer. Semin Oncol 2005;32(2 Suppl 2):S16-S22.
3. Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (Alimta). Oncologist 2004; 9:482-488.
4. Takimoto CH, et al. Phase I and Pharmacokinetic Study of Pemetrexed Disodium (LY231514, MTA, Alimta) in patients with impaired renal function [abstract]. Clin Pharmacol 2001;20:93A.